https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=28904036&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28904036</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1715-5258</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Canadian family physician Medecin de famille canadien</Title><ISOAbbreviation>Can Fam Physician</ISOAbbreviation></Journal><ArticleTitle>Sacubitril-valsartan: novel therapy for heart failure.</ArticleTitle><Pagination><StartPage>697</StartPage><MedlinePgn>697</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sehn</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Doctor of Pharmacy student at the University of Alberta in Edmonton.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Terrence</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Assistant Clinical Professor and Researcher in the Department of Family Medicine at the University of Calgary in Alberta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindblad</LastName><ForeName>Adrienne J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Knowledge Translation and Evidence Coordinator with the Alberta College of Family Physicians in Edmonton.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can Fam Physician</MedlineTA><NlmUniqueID>0120300</NlmUniqueID><ISSNLinking>0008-350X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000613">Aminobutyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>114471-18-0</RegistryNumber><NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance></Chemical><Chemical><RegistryNumber>80M03YXJ7I</RegistryNumber><NameOfSubstance UI="D000068756">Valsartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>WB8FT61183</RegistryNumber><NameOfSubstance UI="C549068">sacubitril and valsartan sodium hydrate drug combination</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000613" MajorTopicYN="N">Aminobutyrates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013777" MajorTopicYN="N">Tetrazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068756" MajorTopicYN="N">Valsartan</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28904036</ArticleId><ArticleId IdType="pmc">PMC5597015</ArticleId><ArticleId IdType="pii">63/9/697</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">25176015</ArticleId></ArticleIdList></Reference><Reference><Citation>Latour-P&#xe9;rez J, Coves-Orts FJ, Abad-Terrado C, Abraira V, Zamora J. Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. Eur J Heart Fail. 2006;8(4):390&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16305826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindblad AJ, Allan GM. Aldosterone antagonists in systolic heart failure. Can Fam Physician. 2014;60:e104. Available from:  www.cfp.ca/content/cfp/60/2/e104.full.pdf. Accessed 2017 Jul 28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922577</ArticleId><ArticleId IdType="pubmed">24522687</ArticleId></ArticleIdList></Reference><Reference><Citation>Moe GW, Ezekowitz JA, O&#x2019;Meara E, Lepage S, Howlett JG, Fremes S, et al. The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol. 2015;31(1):3&#x2013;16. Erratum in: Can J Cardiol 2016;32(3):394.</Citation><ArticleIdList><ArticleId IdType="pubmed">25532421</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlett JG, Chan M, Ezekowitz JA, Harkness K, Heckman GA, Kouz S, et al. The Canadian Cardiovascular Society heart failure companion: bridging guidelines to your practice. Can J Cardiol. 2016;32(3):296&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">26391749</ArticleId></ArticleIdList></Reference><Reference><Citation>Entresto [product monograph]. Dorval, QC: Novartis Pharmaceuticals Canada Inc; 2016.</Citation></Reference><Reference><Citation>Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18(10):1228&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5095784</ArticleId><ArticleId IdType="pubmed">27283779</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee final recommendation: sacubitril/valsartan. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2016.</Citation></Reference><Reference><Citation>Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension. 2017;69(1):32&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">27849566</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>